MedTrace Logo

Dose-Response Study of Probiotic Bacteria BB-12 and CRL-431 in Healthy Young Adults

NCT00611299 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 71

Last updated 2008-03-18

No results posted yet for this study

Summary

The purpose of the study was to investigate the dose-response effect of increasing doses of Bifidobacterium animalis ssp lactis (BB-12) and Lactobacillus paracasei ssp paracasei (CRL-431) on the immune response, blood lipids, gut microflora, recovery from feces and overall tolerance in healthy young adults.

Conditions

Interventions

DIETARY_SUPPLEMENT

BB-12 and CRL 431

Sponsors & Collaborators

  • University of Copenhagen

    lead OTHER

Principal Investigators

  • Kim F Michaelsen, Prof dr med · Michaelsen KF

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-04-30
Completion
2003-11-30

Countries

  • Denmark

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00611299 on ClinicalTrials.gov